+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Mucopolysaccharidosis II (Hunter Syndrome ) Pipeline Analysis and Outlook, 2019

  • ID: 4772501
  • Report
  • May 2019
  • Region: Global
  • 61 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AngioChem Inc
  • Denali Therapeutics Inc
  • GC Pharma
  • Hanmi Pharmaceutical
  • Inventiva Pharma
  • RegenxBio Inc
  • MORE
Mucopolysaccharidosis II (Hunter Syndrome ) pipeline

Mucopolysaccharidosis II (Hunter Syndrome ) pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Mucopolysaccharidosis II (Hunter Syndrome ) R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Mucopolysaccharidosis II (Hunter Syndrome ) report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Mucopolysaccharidosis II (Hunter Syndrome ) as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Mucopolysaccharidosis II (Hunter Syndrome ) with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Mucopolysaccharidosis II (Hunter Syndrome ) pipeline Profiled in detail

Key players actively participating in Mucopolysaccharidosis II (Hunter Syndrome ) pipeline are profiled along with their R&D progress in Mucopolysaccharidosis II (Hunter Syndrome ) treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Mucopolysaccharidosis II (Hunter Syndrome ) pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Mucopolysaccharidosis II (Hunter Syndrome ) treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Mucopolysaccharidosis II (Hunter Syndrome ) pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Mucopolysaccharidosis II (Hunter Syndrome ) pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Mucopolysaccharidosis II (Hunter Syndrome ) pipeline study
  • All recent news and developments related to Mucopolysaccharidosis II (Hunter Syndrome ) drugs are provided
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AngioChem Inc
  • Denali Therapeutics Inc
  • GC Pharma
  • Hanmi Pharmaceutical
  • Inventiva Pharma
  • RegenxBio Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Mucopolysaccharidosis II (Hunter Syndrome ) Disease Overview

3. Mucopolysaccharidosis II (Hunter Syndrome ) Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Mucopolysaccharidosis II (Hunter Syndrome ) Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Mucopolysaccharidosis II (Hunter Syndrome ) Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Mucopolysaccharidosis II (Hunter Syndrome ) companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Mucopolysaccharidosis II (Hunter Syndrome ) Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AngioChem Inc
  • Denali Therapeutics Inc
  • GC Pharma
  • Hanmi Pharmaceutical
  • Inventiva Pharma
  • JCR Pharmaceuticals Co Ltd
  • Laboratorios Del Dr Esteve SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Takeda Pharmaceutical Company Ltd
Note: Product cover images may vary from those shown
Adroll
adroll